This web site is part of the Business Intelligence Division of Informa PLC
Drug Names(s): HolaVax-Typhoid
Deal Structure: HolaVax-Typhoid was originally developed by Acambis. In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The acquisition was completed in September 2008.
In October 2010, Johnson & Johnson and Crucell announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately Euro 1.75 billion in a recommended cash tender offer. The acquisition was declared unconditional and completed in February 2011.
Partners: Johnson & Johnson
Additional information available to subscribers only: